Prescription testosterone is associated with increased risk of infection-related and all-cause reoperations after primary total shoulder arthroplasty in male patients.

Background: Total shoulder arthroplasty (TSA) is an effective procedure for patients with progressive shoulder conditions, but complications like infection and reoperation remain common concerns. Testosterone therapy, often prescribed for hypogonadism, may impact immune function and wound healing, potentially increasing the risk of infections and reoperations. However, the association between testosterone use and reoperation after TSA remains unclear. Methods: We performed a retrospective cohort study using the MarketScan Commercial Claims Database, including 54,850 primary TSAs from 2017 to 2021. Patients with testosterone prescriptions within 12 months before surgery were identified. After matching for demographic and clinical factors, 481 men prescribed testosterone were compared to 962 controls. Cumulative incidences of infection-related and all-cause reoperations at 1, 2, and 3 years postoperatively were analyzed using univariate and multivariate regression models. Data were summarized as odds ratios (ORs) and 95% confidence intervals (CIs). Statistical significance was set at Results: Demographic features were similar between men prescribed testosterone and those not prescribed testosterone. Men prescribed testosterone had statistically significantly higher cumulative incidences of both infection-related reoperations and all-cause reoperations at 1, 2, and 3 years. Multivariate analysis confirmed that testosterone use was an independent risk factor for both infection-related (OR = 4.1, 95% CI [1.0-16.4], Conclusion: Our findings suggest that testosterone use is associated with a higher risk of both infection-related and all-cause reoperations after TSA. Future research is needed to determine whether this association is causal and deepen the understanding of testosterone's effects on wound healing and immune recovery.